> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Participating in Covid Evidence Accelerator
- URL: https://www.fdaweb.com/fda-participating-in-covid-evidence-accelerator/
- Published: 2020-06-18T12:00:00.000Z
- Updated: 2026-09-14T16:18:50.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5147037

FDA says it is participating in the Covid-19 Diagnostics Evidence Accelerator, described as a multi-stakeholder project to advance the development of diagnostics. An online [notice](https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-harness-real-world-data-inform-covid-19-response-efforts?ref=fdaweb.com) says the accelerator is organized by the Reagan-Udall Foundation in collaboration with Friends of Cancer Research.

The notice says the Diagnostics Evidence Accelerator is a companion project to the previously announced Therapeutic Evidence Accelerator that brings together leading experts in health data aggregation and analytics in a unified, collaborative effort to share insights, compare results, and answer key questions to inform the collective Covid-19 response.

Key research questions that will be examined through the Diagnostics Evidence Accelerator, FDA says, include evaluating the real-world performance of SARS-CoV-2 diagnostic tests and antibody tests; how they are best used to tailor testing strategies to specific populations; and what tests results and data may reveal about the prevalence of disease, chains of transmission, and individual and population-level immunity.

“This effort will focus on the use of real-world data to understand whether the presence of antibodies can indicate future immunity and if so, which specific antibodies and epitopes contribute to some level of protection against future infection,” the notice says.